Skip to content

Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy

Added Value of Breast MRI in Evaluation of Pathologic Response in Patients With Locally Advanced Breast Cancer Who Undergo Neoadjuvent Chemotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05301790
Enrollment
45
Registered
2022-03-31
Start date
2022-05-31
Completion date
2024-12-31
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Role of MRI in Evaluation of Breast Cancer

Brief summary

evaluation of pathological response in breast mass by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results

Detailed description

evaluation of pathological response in locally advanced breast masses by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results

Interventions

DEVICEMRI

use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years

Inclusion criteria

* all women referred to the radiology department for breast MRI examination either for screening, evaluation of suspicious lesions onsono-mammography \\ * Patients with locally advanced breast cancer * Patients with early stage breast cancer and chemo-responsive tumour markers (i.e. triple negative, Her2+), who will benefit from downsizing for breast conserving surgery (BCS) * Absolute or Relative contraindications to surgery (advanced age/multiple medical comorbidities) in the setting of estrogen receptor positive tumours (for consideration of neoadjuvant endocrine therapy)3 * Patients must be elder than 18 years old. * patients with accepted renal function

Exclusion criteria

* Patients with metastatic breast cancer. * Patient with breast mass more than 5 cm . * Patients with fungating breast mass . * Patients with stage IV \[tumor spread to chest wall and to skin \]. * pregnant women especially in 1th trimester. * Patient with presence of any paramagnetic substance as pacemakers. * severely ill patients . * patients with claustrophobia. * arrhythmic patients

Design outcomes

Primary

MeasureTime frameDescription
comparison of MRI findings with pathologic resultsbaselineadded value of breast MRI in evaluation of pathologic response in patients with locally advanced breast cancer who undergo neoadjvent chemotherapy

Contacts

Primary ContactDoaa Maher, resident
dm953407@gmail.com01050147500
Backup Contacthasan megally, professor
hasanibrahim48@yahoo.com01006209584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026